Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial

Ofri Mosenzon, Itamar Raz, Deepak L. Bhatt et al.|The Lancet Diabetes & Endocrinology|2019

Cited by 673